Literature DB >> 10799463

Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

A Soininen1, G van den Dobbelsteen, L Oomen, H Käyhty.   

Abstract

The specificity of antibody binding to pneumococcal capsular polysaccharides (Pnc PSs) measured by enzyme immunoassay (EIA) was studied by inhibition of antibody binding by homologous and heterologous PSs. We found extensive cross-reactivity of antibody binding to type 6B, 19F, and 23F PSs but not to type 14 PS, even after treatment with cell wall PS (CPS). The cross-reactive antibody was highly prevalent in sera of infants and adults with naturally acquired antibody, but not in sera of infants and adults immunized with pneumococcal vaccines. However, a type 11A antibody response was seen after vaccination with heterologous PSs. Monoclonal antibodies prepared against a type 6B PS-tetanus toxoid conjugate recognized also other than the specific type of PS in the EIA, implying the possible existence of a cross-reactive epitope. Remarkable differences in specificity among type 6B PS preparations from different manufacturers were found. Moreover, different lots of type 11A PS from the same manufacturer showed differences in specificity. The results suggest that some Pnc PS preparations may contain cross-reactive epitopes or impurities, other than CPS, that are common to many types of Pnc PS. The specificity of antibodies, especially in sera from nonimmunized subjects, measured by EIA can be questioned.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799463      PMCID: PMC95896          DOI: 10.1128/CDLI.7.3.468-476.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  29 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide.

Authors:  D M Musher; M J Luchi; D A Watson; R Hamilton; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

3.  Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

Authors:  D M Musher; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.

Authors:  X Yu; Y Sun; C Frasch; N Concepcion; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Precipitating cross-reactions among pneumococcal types.

Authors:  M Heidelberger
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

6.  Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination.

Authors:  M Koskela
Journal:  Pediatr Infect Dis J       Date:  1987-06       Impact factor: 2.129

7.  Capsular polysaccharides of nongroupable streptococci that cross-react with pneumococcal group 19.

Authors:  C J Lee; K Koizumi; J Henrichsen; B Perch; C S Lin; W Egan
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

8.  C-polysaccharide in a pneumococcal vaccine.

Authors:  U B Sørensen; J Henrichsen
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-12

9.  Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides.

Authors:  J B Robbins; C J Lee; S C Rastogi; G Schiffman; J Henrichsen
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

10.  Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide.

Authors:  M R Wessels; D L Kasper
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

View more
  20 in total

1.  Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides.

Authors:  Raymond E Biagini; Sonela A Schlottmann; Deborah L Sammons; Jerome P Smith; John C Snawder; Cynthia A F Striley; Barbara A MacKenzie; David N Weissman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Specificities and opsonophagocytic activities of antibodies to pneumococcal capsular polysaccharides in sera of unimmunized young children.

Authors:  Anu Soininen; Maijastiina Karpala; Sirkka-Liisa Wahlman; Hannele Lehtonen; Helena Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

3.  Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children.

Authors:  B Simell; T Kilpi; H Käyhty
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

4.  Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera.

Authors:  Isabelle Henckaerts; David Goldblatt; Lindsey Ashton; Jan Poolman
Journal:  Clin Vaccine Immunol       Date:  2006-03

5.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

6.  Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice.

Authors:  W T Jansen; S Hogenboom; M J Thijssen; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines.

Authors:  Jan T Poolman; Carl E Frasch; Helena Käyhty; Pascal Lestrate; Shabir A Madhi; Isabelle Henckaerts
Journal:  Clin Vaccine Immunol       Date:  2009-11-04

8.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

9.  Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.

Authors:  W T Jansen; M Väkeväinen-Anttila; H Käyhty; M Nahm; N Bakker; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

10.  Development and characterization of a multiplex bead-based immunoassay to quantify pneumococcal capsular polysaccharide-specific antibodies.

Authors:  David L Klein; Joseph E Martinez; Michael H Hickey; F Hassouna; K Zaman; Mark Steinhoff
Journal:  Clin Vaccine Immunol       Date:  2012-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.